THERAPY DOSSIER · th-efe2d3ac83d2

Polyethylene glycol 35 (PEG35)

Drug · Osmotic laxative; laxative (ChEMBL mechanism records; no molecular target assigned)

Evidence & regulatory context

Mechanism: Osmotic laxative; laxative (ChEMBL mechanism records; no molecular target assigned)
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Preclinical/no trial
ChEMBL record: CHEMBL1201478 ↗
ChEMBL max phase: 3 / 4 (development scale, not regulatory approval)
Synonyms: Macrogol; Polyethylene glycol; Polyethylene oxide; E-1521
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32019239 ↗2020Reported benefit

Polyethylene Glycol 35 (PEG35) Protects against Inflammation in Experimental Acute Necrotizing Pancreatitis and Associated Lung Injury.

RatChemical/toxinWistarMaleIntravenous, via the penile vein10 mg/kgProphylactic administration before induction of acute necrotizing pancreatitis,…

Model: Acute necrotizing pancreatitis induced by retrograde infusion of 5% sodium taurocholate into the biliopancreatic duct, with associated lung injury assessed at 3 h

Prophylactic PEG35 reduced plasma lipase, local and systemic inflammatory mediator expression (IL-6, IL-1beta, TNF-alpha, CXCL2), adhesion molecule levels, neutrophil recruitment and cell death in both pancreas and lung. Therapeutic PEG35 significantly reduced associated lung injury even when the p…

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…